IGC Pharma, Inc.IGCEarnings & Financial Report
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
IGC Q3 FY2025 Key Financial Metrics
Revenue
$191.0K
Gross Profit
$99.0K
Operating Profit
$-2.9M
Net Profit
$-1.8M
Gross Margin
51.8%
Operating Margin
-1517.8%
Net Margin
-953.4%
YoY Growth
-53.6%
EPS
$-0.02
IGC Pharma, Inc. Q3 FY2025 Financial Summary
IGC Pharma, Inc. reported revenue of $191.0K (down 53.6% YoY) for Q3 FY2025, with a net profit of $-1.8M (down 6.1% YoY) (-953.4% margin). Cost of goods sold was $92.0K, operating expenses totaled $3.0M.
Key Financial Metrics
| Total Revenue | $191.0K |
|---|---|
| Net Profit | $-1.8M |
| Gross Margin | 51.8% |
| Operating Margin | -1517.8% |
| Report Period | Q3 FY2025 |
IGC Pharma, Inc. Annual Revenue by Year
IGC Pharma, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.2M).
IGC Pharma, Inc. Quarterly Revenue & Net Profit History
IGC Pharma, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $191.0K | -53.6% | $-1.8M | -953.4% |
| Q2 FY2025 | $328.0K | +20.6% | $-1.6M | -487.5% |
| Q4 FY2024 | $257.0K | +26.0% | $-1.8M | -711.7% |
| Q3 FY2024 | $412.0K | +41.6% | $-1.7M | -416.7% |
| Q2 FY2024 | $272.0K | -51.0% | $-2.4M | -874.3% |
| Q1 FY2024 | $295.0K | +78.8% | $-2.9M | -978.0% |
| Q4 FY2023 | $204.0K | -38.6% | $-5.6M | -2739.7% |
| Q3 FY2023 | $291.0K | +44.1% | $-2.5M | -842.3% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $291000 | $204000 | $295000 | $272000 | $412000 | $257000 | $328000 | $191000 |
| YoY Growth | 44.1% | -38.6% | 78.8% | -51.0% | 41.6% | 26.0% | 20.6% | -53.6% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.5M | $11.3M | $9.9M | $10.6M | $10.4M | $9.1M | $7.9M | $9.7M |
| Liabilities | $2.4M | $2.2M | $2.6M | $2.7M | $3.0M | $2.8M | $1.9M | $1.7M |
| Equity | $14.1M | $9.1M | N/A | $7.9M | $7.4M | $6.3M | $6.1M | $8.1M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-1.6M | $-526000 | $-1.8M | $-996000 | $-1.4M | $-2.1M |